Epigenetics Market Size to Reach USD 6.35 Bn By 2032

The global epigenetics market size is projected to reach around USD 6.35 billion by 2032, increasing from USD 2.14 billion in 2023 and is expanding at a healthy CAGR of 12.82% between 2023 to 2032.

The global epigenetics market size was valued at USD 1.9 billion in 2022, According to Precedence Research. North America dominated the market with the highest market share of 40% in 2022.

Key Highlights:

• In 2022, reagents product segment dominated the market.
• From 2023 to 2032, the kits product segment is anticipated to expand at the highest compound annual growth rate (CAGR).
• DNA methylation technique segment held the majority share in 2022.
• In 2022, the oncology application segment accounted for over 70% of the global market revenue.
• From 2023 to 2032, the non-oncology application is expected to grow at a higher rate.
• The end-user market was driven by pharmaceutical and biotech companies in the world in 2022.
• From 2023 to 2032, the end-user market for academic and research institutions is predicted to develop at the quickest CAGR.

Epigenetics is defined as a specialized branch of genetics that deals with the variations in cellular and physiological characteristics induced by external factors. For instance, certain genes switch on and off, modifying the cell’s interpretation of the genes without being affected by the shift in genotype. Epigenetic modifications in an organism are phenotypic changes rather than genotypic ones, although the original genomic sequence is not altered. Epigenetic changes are a vital part of the developmental process as they result in dynamic changes in response to environmental stimuli.

Epigenetics is often associated with the investigation of changes in heritable phenotypes in several conditions, such as cardiovascular dysfunction, various cancers, respiratory infections, cognitive abnormalities, reproductive issues, and autoimmune disorders. Pesticides, hormones, heavy metals, cigarettes, environmental changes, radiation, viruses, and nutrients are some agents documented to be linked either directly or indirectly with several epigenetic mechanisms. Increasing exposure to such agents due to changing lifestyles, pollution and environmental variations strongly contributes to the growth of the epigenetics market.

Download the Sample Copy@ https://www.precedenceresearch.com/sample/2633

In the therapeutic sector, epigenetics provides specialized restorative measures. The prevalence of disorders like cancer, cardiovascular conditions, fertility issues, etc., is linked to the market’s growth due to the subsequent increase in related research and development activities. Growing investments and financial aid from various organizations, as well as increasing collaborations between key players, support this cause, further strengthening market growth. Furthermore, an increase in disposable income, awareness regarding epigenetics, and easy-to-use kits will greatly aid the overall industry during the forecast period. At the same time, advancements in DNA sequencing techniques combined with artificial intelligence and automation are expected to generate new avenues for future development.

Regional Stance:

North America accounted for more than 40% of revenue share in 2022 and is expected to lead the global epigenetics market over the forecast period due to the region’s growing tumour patient population as well as the advanced economies of countries like the United States and Canada, where people can afford the cost of cancer therapies due to their higher income levels.

People are expected to enroll in cancer treatment as a result of the government’s outstanding healthcare reimbursement regulations, which will support regional growth. This industry may benefit from increased funding for epigenetics research in the US. With a USD 125 million capital, Chroma Medicine, Inc. (Chroma) was established in November 2021 with the goal of treating a broad spectrum of disorders and being the go-to method for controlling gene expression. The market in this area ought to expand as a result of the previously mentioned variables.

The Asia-Pacific area is anticipated to grow substantially due to the availability of comparatively cheaper therapies and the rise in medical tourism in countries like China and India. The growing number of strategic alliances between private companies and international organizations to expand their customer bases might potentially be connected to regional expansion.

Ask Here for Customization@ https://www.precedenceresearch.com/customization/2633

Epigenetics Market Scope

Growth Factors:

• Cancer arises from the malignancy of a single or a group of cells. The prevalence of these conditions globally has been a challenge. According to a report published by the American Cancer Society, in 2023 alone, 1,958,310 new cancer diagnoses were confirmed, with 609,820 associated deaths in the United States. Epigenetics combat this by targeting the malignant cells in the host, as compared to traditional cancer therapies. The International Human Epigenetic Modification Collaboration (IHEC), National Cancer Institute (NCI), and Ministry of Health are some organizations that actively support the cause via funds and awareness campaigns. Thus, the growth of cancer incidences globally is anticipated to drive the development of the epigenetics industry greatly.
• Increasing awareness in terms of formerly overlooked conditions has appeared on the tracks of the global pandemic. The multitude of acknowledgements received for these hidden dangers generates lucrative possibilities for the growth of the healthcare industry, particularly the biotechnology sector. Some of these diseases utilize therapeutics based on genetic constituents. Innumerable organizations have been investigating these mechanisms to develop necessary vaccines and medications for anomalies that currently have no effective therapies dedicated to them. For instance, the National Institutes of Health (NIH) actively provides investments for epigenetics studies via the epigenomics program. This initiative was founded to facilitate the active growth of epigenetic research across the globe.
• A trend of increasing disposable income has recently been observed among the upper working classes. Combined with the growing awareness of epigenetics and at-home use kits providing epigenetic analysis, the diagnostic segment of the epigenetic market has experienced a sudden rise in demand.

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 650 460 3308

Market Potential:

According to the World Health Organization data, as of April 2023, the weighted average health has increased in most high-income countries from 0.21% to 0.25% of their GDP. Epigenetic interventions have been found to be highly effective in dealing with several types of cancers, and the investments allow individual researchers and small startups to explore their potential while coping with non-oncology conditions that cannot be prescribed by traditional treatment methods.

Emergence of advanced technologies in the genetic engineering is observed to open opportunities to the market.

Innovations in technology genetic engineering show substantial potential in the market. These options allow the market to develop in new directions, emerging as a game-changer, fulfilling the therapeutic needs associated with complex disorders. Pharmaceutical companies are slowly shifting their focus toward developing and commercializing these therapies.

Related Reports:

• DNA Synthesizer Market: The global DNA synthesizer market size was exhibited at USD 274.11 million in 2022 and is expected to surpass around USD 1,070.02 million by 2032 with an enhanced CAGR of 14.59% during the forecast period 2023 to 2032.
  
• DNA Polymerase Market: The global DNA polymerase market size accounted for USD 329.1 million in 2022 and it is expected to hit around USD 582.6 million by 2032, poised to grow at a CAGR of 5.87% over the forecast period 2023 to 2032.
  
• Gene Synthesis Market: The global gene synthesis market size was estimated at USD 2.10 billion in 2022 and is expected to hit around USD 17.99 billion by 2032, registering a CAGR of 23.97% over the forecast period 2023 to 2032.

Industry Spotlight:

• In January 2023, Agilent Technologies, Inc. announced the acquisition of a company that targeted enrichment workflow development for clinical researchers utilizing NGS methods to study cancers, Avida Biomed.
• In February 2022, Zenith Epigenetics Ltd. documented the administration of the first dose of the combination of ZEN-3694, OPDIVO and YERVOY to a patient. ZEN-3694 is a BET inhibitor, while PD-1 is an immune checkpoint inhibitor developed by Bristol Myers Squibb. This achievement was a part of the National Institutes of Health-sponsored solid tumor cancer trial conducted at the National Cancer Institute (NCI).
• In February 2022, a developer of a new and disruptive DNA sequencing platform, Element Biosciences, Inc., established a partnership with Dovetail Genomics. This collaboration demonstrated the value and performance of Dovetail’s proximity ligation-based-based next-generation sequencing (NGS) library prep solutions on Element’s AVITI System.

Market Key Players:

• Bio-Rad
• Illumina
• QIAGEN
• Thermo Fisher
• Active Motif
• Diagenode
• Agilent
• Merck Millipore
• Abcam
• New England Biolabs
• PerkinElmer
• Zymo Research

Company synopsis:

Bio-rad Laboratories Inc.

One of the top five life science firms in the world is Bio-Rad. It provides software, tools, consumables, reagents, and other goods and services to meet the needs of many industries, including gene expression, cell biology, protein purification and quantification, drug development and production, food safety, and others. Bio-Rad Laboratories, Inc. purchased Curiosity Diagnostics, a producer of state-of-the-art technological solutions for the medical diagnostic and healthcare sectors, in August 2022. The Polish-based corporation was registered with a $170 million capital. It includes up to $70 million in possible future milestone payments in addition to about $100 million in cash.

Agilent technologies

Agilent is a well-known global leader in applied chemicals, diagnostics, and life sciences. The company provides a wide range of instruments, consumables, apps, services, and knowledge to laboratories worldwide with diligence. This steadfast dedication makes it possible for clients to obtain the knowledge they actively seek. Agilent Technologies Inc. purchased Avida Biomed in January 2023. Avida Biomed is a young life sciences company that develops high-performance target enrichment procedures with unique features for clinical researchers employing next-generation sequencing (NGS) tools to study cancer.

Merck Group

The Merck Group is a multinational corporation based in Germany with a complex network of about 250 locations. The corporation, which has its headquarters in Darmstadt, Germany, primarily engages with research and technology. With activities spanning 66 countries, Merck employs over 60,000 brilliant and industrious people. With research & development centres in Darmstadt, Boston, Tokyo, and Beijing, as well as smaller sites in Israel, Taiwan, France, India, South Korea, and the UK, the firm principally operates in Asia, Oceania, Europe, Africa, and the US. Merck reported a net sales figure of 22,232 million euros in their 2022 financial report.

Market Segmentation

By Product

• Kits
• Reagents
• Enzymes
• Instruments and Consumables
• Bioinformatic Tools

By Technology

• DNA Methylation
• Histone Modification
• Other Technologies

By Application

• Oncology
  • Solid Tumors
  • Liquid Tumors
• Non - oncology
  • Metabolic Diseases
  • Developmental Biology
  • Immunology
  • Cardiovascular Diseases
  • Other

By End-User

• Academic and Research Institutes
• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa

Browse Table of Contents: https://www.precedenceresearch.com/table-of-content/2633

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Immediate Delivery Available | Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/2633

Unlocking Market Insights through Data Excellence

The “Precedence Statistics” flexible dashboard is a powerful tool that offers real-time news updates, economic and market forecasts, and customizable reports. It can be configured to support a wide range of analysis styles and strategic planning needs. This tool empowers users to stay informed and make data-driven decisions in various scenarios, making it a valuable asset for businesses and professionals looking to stay ahead in today’s dynamic and data-driven world.

Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com

About Us

Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

Web: https://www.precedenceresearch.com/

Our Blogs:

https://www.towardshealthcare.com

https://www.towardspackaging.com

For Latest Update Follow Us:

Linkedin | Facebook | Twitter